LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016.
“We are continuing to build a diverse pipeline based on our deuterium drug development platform as evidenced by our newest clinical candidate, CTP-543, for the treatment of alopecia areata,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “By year end, we expect to complete Phase 1 single and multiple ascending dose trials for CTP-543 as well as open an Investigational New Drug Application with CTP-656, our drug candidate for cystic fibrosis, to initiate a Phase 2 trial. Both alopecia areata and cystic fibrosis represent disease areas where we believe our compounds can offer distinct patient benefits and where we believe we can independently develop a product. We are excited about the prospects for our pipeline in which we will have two wholly-owned drug candidates in efficacy studies next year.”
“We are continuing to build a diverse pipeline based on our deuterium drug development platform as evidenced by our newest clinical candidate, CTP-543, for the treatment of alopecia areata,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “By year end, we expect to complete Phase 1 single and multiple ascending dose trials for CTP-543 as well as open an Investigational New Drug Application with CTP-656, our drug candidate for cystic fibrosis, to initiate a Phase 2 trial. Both alopecia areata and cystic fibrosis represent disease areas where we believe our compounds can offer distinct patient benefits and where we believe we can independently develop a product. We are excited about the prospects for our pipeline in which we will have two wholly-owned drug candidates in efficacy studies next year.”
